Kelly Hensley

800 citations

21 papers · 438 indexed · h-index 11

Co-authors: Brian P. Lipsky K. Sadhu Sharon L. Wolda León F. Garcı́a-Martı́nez Chanchal Sadhu Scott I. Simon Donald E. Staunton Harold J. Ting
Topics: Cancer Immunotherapy and Biomarkers (5 papers)HER2/EGFR in Cancer Research (5 papers)CAR-T cell therapy research (4 papers)
Cited by: Immunology Nephrology Neurology
Journals: Journal of Biological Chemistry Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States Canada Sweden

In The Last Decade

Kelly Hensley

21 papers receiving 425 citations

Peers

Countries citing papers authored by Kelly Hensley

Since Specialization

Citations

This map shows the geographic impact of Kelly Hensley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Hensley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Hensley more than expected).

Fields of papers citing papers by Kelly Hensley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Hensley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Hensley. The network helps show where Kelly Hensley may publish in the future.

Co-authorship network of co-authors of Kelly Hensley

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Hensley. A scholar is included among the top collaborators of Kelly Hensley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Hensley. Kelly Hensley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer 2023 ·Cancer Research Communications ·(unknown),(unknown),(unknown),Kelly Hensley,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Michelle Ulrich,Scott Peterson,Anita Kulukian	6
2	Abstract 1522: SGN-B6A induces immunogenic cell death as an additional mechanism of action 2023 ·Cancer Research ·(unknown),(unknown),John J. Gosink,Michelle Ulrich,(unknown),(unknown),(unknown),Liya Huang,Kelly Hensley,Piper M. Treuting,Kerry Klussman,(unknown),(unknown),Roma Yumul,(unknown),Robert P. Lyon	2
3	Abstract 4892: MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads 2023 ·Cancer Research ·Michelle Ulrich,Kerry Klussman,John J. Gosink,(unknown),Kelly Hensley,Piper M. Treuting,Nikhil J. Parekh,Elizabeth Gray,Shyra J. Gardai	2
4	1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors 2022 ·Regular and Young Investigator Award Abstracts ·(unknown),(unknown),Bernard A. Liu,(unknown),John J. Gosink,(unknown),(unknown),Kelly Hensley,(unknown),Albina Nesterova,(unknown),Anthony Cao,Christine O’Day,Ryan A. Heiser,Timothy S. Lewis,Shyra J. Gardai,(unknown),Masashi Shimazaki,(unknown),Sharsti Sandall	10
5	Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer 2022 ·Cancer Research ·(unknown),(unknown),(unknown),Anthony Lee,(unknown),Amit Garg,Christine O’Day,Esther S. Trueblood,Jennifer Wright,Mark Bieda,Charles W. Caldwell,Kelly Hensley,(unknown),Bernard A. Liu,Masashi Shimazaki,Sharsti Sandall	2
6	854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models 2021 ·SHILAP Revista de lepidopterología ·Elizabeth Gray,Angela Epp,Michelle Ulrich,(unknown),Kelly Hensley,(unknown),(unknown),(unknown),(unknown),(unknown),John J. Gosink,Rogely Boyce,Esther S. Trueblood,Piper M. Treuting,(unknown),(unknown),Jason Schrum,(unknown),Shyra J. Gardai	3
7	783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors 2021 ·SHILAP Revista de lepidopterología ·Byron H. Kwan,(unknown),(unknown),Changpu Yu,(unknown),(unknown),(unknown),Jessica K. Simmons,Kelly Hensley,Christina L. Zuch de Zafra,Haley D. Neff‐LaFord,Shawna Hengel,Andres Forero‐Torres,Heather Van Epps	2
8	Abstract 1962: Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors 2020 ·Cancer Research ·(unknown),Anita Kulukian,(unknown),(unknown),Albina Nesterova,Kelly Hensley,Michelle Ulrich,Nicole Stevens,Scott Peterson	2
9	Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers 2020 ·Cancer Research ·Bernard A. Liu,(unknown),(unknown),John J. Gosink,(unknown),(unknown),Anthony Cao,(unknown),Albina Nesterova,Kelly Hensley,Julia H. Cochran,Shyra J. Gardai,Timothy S. Lewis	24
10	617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death 2020 ·SHILAP Revista de lepidopterología ·Elizabeth Gray,Kelly Hensley,(unknown),Esther S. Trueblood,John J. Gosink,(unknown),Kaleb Smith,Céline Jacquemont,Mark Bieda,Jason Gow,Jeffrey R. Harris,Lauren Brady,Ibrahima Soumaoro,Shweta Jain,Leonardo Nicacio,Shyra J. Gardai	7
11	Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia 2020 ·Toxicological Sciences ·(unknown),Rebecca Goldstein,Brendon Frank,(unknown),Chi-Ming Li,Oliver Homann,Kelly Hensley,Benjamin D. Brooks,Xiaoting Wang,Qinghong Yan,(unknown),Gregor B. Adams,Michael Boyle,Tara Arvedson,Hervé Lebrec	15
12	Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy. 2019 ·Journal of Clinical Oncology ·(unknown),Rebecca Goldstein,Brendon Frank,(unknown),Chi-Ming Li,Bradford W. Gibson,Oliver Homann,Kelly Hensley,(unknown),Qinghong Yan,(unknown),Gregor B. Adams,Michael C. Boyle,Tara Arvedson,Hervé Lebrec	3
13	PAC1 receptor mRNA and protein distribution in rat and human trigeminal and sphenopalatine ganglia, spinal trigeminal nucleus and in dura mater 2018 ·Cephalalgia ·Kelly Hensley,(unknown),(unknown),Keith J. Page,Hantao Liu,Chang-Jin Choi,Di Shi,Cen Xu,Lars Edvinsson,Silke Miller	17
14	Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism 2017 ·Calcified Tissue International ·(unknown),James Tomlinson,Shawn T. Alexander,Kelly Hensley,Chun-Ya Han,Denise Dwyer,Marina Stolina,Charles R. Dean,William G. Goodman,William G. Richards,Xiaodong Li	37
15	Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism 2017 ·Bone ·Xiaodong Li,(unknown),Frank Asuncion,Mario Grisanti,Shawn T. Alexander,Kelly Hensley,Chun-Ya Han,Qing‐Tian Niu,Denise Dwyer,(unknown),Marina Stolina,Charles R. Dean,Michael S. Ominsky,Hua Zhu Ke,James Tomlinson,William G. Richards	25
16	In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator 2016 ·Journal of Biological Chemistry ·Ingrid C. Rulifson,Patrick Collins,(unknown),Dana Nojima,Ki Jeong Lee,(unknown),Jamila Gupte,Kelly Hensley,(unknown),Cynthia Cam,James B. Rottman,(unknown),William G. Richards,Yang Li	14
17	GPR34 is not required for mast cell degranulation induced by IgE or lysophosphatidyl-L-serine (36.1) 2009 ·The Journal of Immunology ·Christine Vissinga,Kelly Hensley,Jacqueline Kirchner	2
18	A Central Nervous System-Restricted Isoform of the Interleukin-1 Receptor Accessory Protein Modulates Neuronal Responses to Interleukin-1 2009 ·Immunity ·Dirk E. Smith,Brian P. Lipsky,Chris B. Russell,Randal R. Ketchem,Jacqueline Kirchner,Kelly Hensley,Yangyang Huang,Wilma Friedman,Vincent Boissonneault,Marie-Michèle Plante,Serge Rivest,John E. Sims	101
19	CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity 2007 ·Journal of Leukocyte Biology ·Chanchal Sadhu,Harold J. Ting,Brian P. Lipsky,Kelly Hensley,León F. Garcı́a-Martı́nez,Scott I. Simon,Donald E. Staunton	81
20	Differential Expression of the Cyclic GMP-stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells 1999 ·Journal of Histochemistry & Cytochemistry ·K. Sadhu,Kelly Hensley,(unknown),Sharon L. Wolda	58

About Kelly Hensley

Kelly Hensley is a scholar working on Immunology and Allergy, Oncology and Nephrology, having authored 21 papers that have together received 438 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), HER2/EGFR in Cancer Research (5 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Immunology (159 citations), Nephrology (48 citations) and Neurology (41 citations). Kelly Hensley has collaborated with scholars based in United States, Canada and Sweden. Frequent co-authors include Brian P. Lipsky, K. Sadhu, Sharon L. Wolda, León F. Garcı́a-Martı́nez, Chanchal Sadhu, Scott I. Simon, Donald E. Staunton, Harold J. Ting, Jacqueline Kirchner and Marie-Michèle Plante. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact